"SteadyMed is dedicated to supporting the PH community, and we hope that BePHenomenal.com helps empower and inspire this community to live their most PHenomenal lives," said Marylyn Rigby, Senior Director, Investor Relations and Marketing at SteadyMed. "We are always excited to honor the incredible people in the PH community. We are especially grateful to do so during Pulmonary Hypertension Awareness month and look forward to sharing more amazing stories from members of this community through our Thunderclap and photo and video drive."PH is a condition defined as high blood pressure in the lungs. One form of PH, pulmonary arterial hypertension (PAH), is a progressive and life-changing chronic disease. Symptoms, which worsen over time and significantly impact patients' lives, can include shortness of breath, dizziness and fatigue. There is no cure for the disease, which can become life-threatening within a few years if left untreated. About SteadyMedSteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements about the company's ability to advance its development-stage product candidates, including Trevyent. Forward-looking statements reflect the company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that Trevyent does not demonstrate clinical superiority to existing parenteral treprostinil products, that Trevyent is not approved for commercialization by the FDA, that Trevyent is not granted orphan drug exclusivity, and the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q filed on November 14, 2016. The company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.
Contact:Marylyn RigbySenior Director, Investor Relations and Marketing925email@example.com